After EGFR-TKI treatment, the patients who were TKI-sensitizing EGFR mutations had a median progression-free survival (PFS) of 342 days (95% CI: 290.6-393.4), and those who were tumor-tissue EGFR M- had a median PFS of 60 days (95% CI: 0.0-123.8); this difference was statistically significant (P < 0.001, Figure 4A). The gene discussed is EGFR; the disease is neoplasm.